Illumina Announces Long Reads

Illumina recently announced the upcoming availability of long-read technology at the 40th Annual J.P. Morgan Healthcare Conference, in a press release and on Illumina’s Genomics Research Hub.  The new long-read sequencing assay is code-named Infinity and is predicted to launch in the second-half of 2022.  However, no firm release date has been set.

 

Illumina states that the Infinity assay will have several useful features that are superior to existing short-read technologies:

  • Infinity will yield up to 10 Kb (kilobase) contiguous read lengths.  This is in contrast to typical short-read read lengths in the 2x150bp (300bp) – 2x300bp (600bp) (base pair) range.
  • Illumina states that Infinity will yield 10X throughput vs. long-read technologies from competing vendors.  By throughput we assume they mean the number of reads generated per sample in a typical sequencing run.  This may or may not be very important as Illumina’s SBS (sequencing-by-synthesis) protocol is completely different from Oxford Nanopore’s nanopore direct current sequencing method or PacBio’s SMRT (single-molecule real-time) sequencing method.
  • Illumina states that the Infinity assay will require 90% less DNA input vs. long-read technologies from competing vendors.  This could be significant for some applications where the quantity (mass, concentration) of DNA is limited.
  • The Infinity assay will be implemented on Illumina’s existing sequencer platforms (ca. 20,000 worldwide).  This is quite important as there will be no need for laboratories to upgrade to new instruments or expend precious CapEx funds replacing existing machines.

 

There could be numerous benefits from the Infinity long-read technology, including:

With short-read methods it can be difficult or impossible to map or assemble long stretches of repetitive sequences and homopolymer sequences.  Long-reads can often resolve these genomic regions as the long-reads can span their entire length.  Likewise, long-reads can resolve many types of structural variants, such as long insertions and deletions (indels), translocations, inversions, interspersed duplications and tandem duplications.  Short-reads have trouble with these large structural variations in genomic sequence.

 

It will be important to see if the Infinity assay long-read basecall quality (Phred Q-scores) is similar to existing short-reads.  On Illumina platforms we’re accustomed to Q > 30 (99.9% accuracy) basecall quality scores. We’ll have to see if the Infinity assay long-reads maintain this level of accuracy.

 

We will keep track of developments with the Infinity assay and likely implement it in our Lab as soon as it becomes available.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published.